Related references
Note: Only part of the references are listed.Myelodysplastic Syndromes: A New Decade
Virginia O. Volpe et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes
Amit Verma et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
Rami S. Komrokji
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review
Sophie Park et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
E Hellström-Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)